NEWS

Schlieren / Zurich, Switzerland – January 24, 2023 – Memo Therapeutics AG (“MTx”), an innovator in the field of antibody discovery and development, announced today positive safety and tolerability data from a Phase I clinical trial with AntiBKV, an antibody targeting BK polyomavirus (“BKV”) infection in renal transplant patients, meeting its primary endpoint

Schlieren / Zurich, Switzerland – Mai 31, 2022 – Memo Therapeutics AG (“MTx”), an innovator in the field of antibody discovery and development, announced today the initiation of a phase 1 clinical study targeting BK polyomavirus (“BKV”) infection in renal transplant patients.

Schlieren, Switzerland – February 16, 2022 – Memo Therapeutics AG (“MTx”), an innovator in the field of antibody discovery and development, announced today the close of an oversubscribed Series B financing round led by Swisscanto Invest at CHF37 million after securing an additional CHF23 million from a combination of strategic and financial investors, including Adjuvant Capital, Fresenius Medical Care Ventures, GF Group, Verve Ventures, Vesalius Biocapital and Zürcher Kantonalbank.

Schlieren, Switzerland – July 6, 2020 – Memo Therapeutics AG (“Memo”), an innovator in the field of antibody discovery and development, announced today the appointment of Elias Papatheodorou as Chairman of the Board of Directors. He is joined by Dr. Thomas Taapken, who has been elected as a Member of the Board of Directors.

Schlieren, Switzerland – May 17, 2020 – Memo Therapeutics AG (“Memo”), an innovator in the field of antibody discovery and development, announced today that MTX-COVAB, its human-derived antibody against SARS-CoV-2, the virus that causes COVID-19, has shown efficacy against both the original virus as well as the UK variant (B.1.1.7).  Memo is now preparing MTX-COVAB for clinical evaluation.

Schlieren, Switzerland – November 6, 2020 – Memo Therapeutics AG, an innovator in the field of antibody discovery and immune repertoire analysis, announced today that the company has raised CHF 14 million in Series B financing. The round was led by Swisscanto Invest by Zürcher Kantonalbank and included BERNINA BioInvest, as well as new private investors and existing investors Investiere, Schroder Adveq, Jaquet Partners, and Redalpine.

Zurich, Switzerland, and Vilnius, Lithuania – June 25, 2020 – Memo Therapeutics AG and Northway Biotechpharma, a leading biopharmaceutical Contract Development and Manufacturing Organization (CDMO), have signed a Development and Manufacturing Agreement for a therapeutic antibody.

Schlieren, March 18, 2020. Memo Therapeutics AG is deploying its microfluidic technology platform DROPZYLLA®, to create cognate recombinant libraries from COVID-19 patients who overcame infection in a particularly efficient manner (“elite controllers”). In comparison to other technlogies having a capture rate of far below 5%, MTxs libraries comprise at least 80% of a patient’s antibody repertoire. Capturing essentially the whole antibody repertoire is of crucial importance since antibodies with neutralizing activity represent only a minority of the antibodies made by the human immune system.

Memo Therapeutics AG announced today that it is entering preclinical development with its first drug candidate an anti-BKV antibody isolated from humans for the treatment of BK virus infection after renal transplantation.

Memo Therapeutics AG made it to the top 100 of Swiss startups for the third time in a row and is within the top 5 biotech companies. See entire list of companies.

Memo Therapeutics AG announces proof of concept of its huMemoMAB^TM antibody technology platform

Memo Therapeutics AG announces completion of a first commercial project validating its proprietary MemoMAB™ antibody technology platform.

MEMO’s abstract has been accepted for Poster Discussion presentation...